A:TACE

4 trials

Sponsors

Renji Hospital affiliated to Shanghai Jiaotong University school of Medicine, Chinese PLA General Hospital, Fudan University Shanghai Cancer Center

Conditions

HCCliver cancerprimary hepatic carcinoma

Early Phase 1

An exploratory study on the efficacy of Regofinib+TACE+MWA in patients with advanced hepatocellular carcinoma

Active, not recruitingChiCTR2000037411

Renji Hospital affiliated to Shanghai Jiaotong University school of Medicineliver cancer

Start: 2020-10-01Updated: 2020-10-13

Phase 1

TACE combined with nimotuzumab in the treatment of unresectable HCC

Active, not recruitingChiCTR2200061142

Chinese PLA General HospitalHCC

Start: 2022-06-01Updated: 2023-03-26

TACE combined with PD-1/PDL-1 in the treatment of unresectable HCC

Active, not recruitingChiCTR2200061143

Chinese PLA General HospitalHCC

Start: 2022-06-01Updated: 2023-03-26

Phase 4

A randomized controlled multicenter clinical study of compound Kushen Injection combined with TACE in treating the primary hepatic carcinoma.

RecruitingChiCTR-IPR-15005894

Fudan University Shanghai Cancer Centerprimary hepatic carcinoma

Start: 2014-12-23Updated: 2017-04-18